Chris Prunty | QVG Capital
A big batch of 300 entries suggests the tide may be turning for small industrials.
George Soros’s first business partner, Jim Rogers, would love Aussie Small Caps. As the author of a book called ‘Hot Commodities’ Jim would have found a happy hunting ground in Aussie smalls over the last few years.
Having said this, if the recently announced S&P/ASX 300 entries are any indication, the tide may be turning back towards small cap industrials. For the first time in years, there were more small cap industrial stocks added to this key benchmark than resource companies.
For the past few years, QVG Capital has been writing on Livewire about index changes, with a particular focus on the proportion of unprofitable companies entering the S&P/ASX 300. On 6 September it was announced a jumbo cohort of 16 companies will be added to the S&P/ASX 300. We have previously discussed the lack of quality of 300 entries but this batch is showing signs of improvement - 10 of the 16 are actually making a buck.
For those wondering about the significance of the S&P/ASX 300, it’s the benchmark that index funds such as the $16.1 billion Vanguard Australian Shares Index (ASX: VAS) seek to replicate. It’s also the pool that many fundamental portfolio managers use for their investable universe. With a new batch of additions entering the index in September, we felt it was worth reviewing the current crop.
Here goes:
Table: 16 stocks that have been added to the S&P/ASX300 (Source: QVG Capital)
The table above shows the 16 stocks that have recently been promoted into the index. It’s notable that there were more industrials – 7 – than resources – 6 – added, with 3 biotech’s rounding out the additions.
Clarity, Immutep and Opthea are the biotech’s being promoted into the 300. None make money yet but biotech investors have had big wins out of Telix (TLX, $6B market cap) and Neuren (NEU, $1.7B), so will be hoping these three can defy the odds and come in a winner. For the technical analysts, Clarity has a chart to die for, but the other two are a little more aimless and we note this is Opthea’s second crack at the 300.
Recently, the themes in resources have been clear. Last rebalance saw a bunch of uranium names added just in time to mark the top market, while the prior two years were all about Lithium (and we know how that has ended). Apart from a couple of Copper names, it’s a mixed bag of commodities with Coal, Gold and specialty metals all featuring.
Of more interest this time around is the fact there are several high-growth, high-quality small industrial names coming into the 300. Names like Gentrack, GyG, Nuix, RPMGlobal and Superloop all have identifiable competitive advantages, are profitable and are growing above market.
We suggest the following:
If you buy an index product, be aware you’re buying the good, the bad and the ugly.
Fundamentals such as profitability, durability of those profits, and efficiency (i.e. how much capital is required to generate those profits) drive share prices in the long run.
And finally, stocks with weak fundamentals that are over-valued for technical reasons can present great shorting opportunities; ones the QVG Long Short fund seeks to take advantage of.
The August reporting season saw significant fluctuations in stock prices, sometimes unrelated to the fundamental value of companies. Volatility creates opportunity for active investors to buy shares at attractive valuations and to exit overpriced stocks during these pronounced market swings.
All prices and analysis at 9 September 2024. This document was originally published in Livewire on 9 September 2024. This information has been prepared by QVG CAPITAL PTY LTD (AFSL No. 507070, ABN 69 619 271 886).
The content is distributed by WealthHub Securities Limited (WSL) (ABN 83 089 718 249)(AFSL No. 230704). WSL is a Market Participant under the ASIC Market Integrity Rules and a wholly owned subsidiary of National Australia Bank Limited (ABN 12 004 044 937)(AFSL No. 230686) (NAB). NAB doesn’t guarantee its subsidiaries’ obligations or performance, or the products or services its subsidiaries offer. This material is intended to provide general advice only. It has been prepared without having regard to or taking into account any particular investor’s objectives, financial situation and/or needs. All investors should therefore consider the appropriateness of the advice, in light of their own objectives, financial situation and/or needs, before acting on the advice. Past performance is not a reliable indicator of future performance. Any comments, suggestions or views presented do not reflect the views of WSL and/or NAB. Subject to any terms implied by law and which cannot be excluded, neither WSL nor NAB shall be liable for any errors, omissions, defects or misrepresentations in the information or general advice including any third party sourced data (including by reasons of negligence, negligent misstatement or otherwise) or for any loss or damage (whether direct or indirect) suffered by persons who use or rely on the general advice or information. If any law prohibits the exclusion of such liability, WSL and NAB limit its liability to the re-supply of the information, provided that such limitation is permitted by law and is fair and reasonable. For more information, click here.